Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma
Cancers · 27.12.2023 · 16 (1) · 141
DOI: 10.3390/cancers16010141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 27.12.2023. Verfasst von Nadia Ninosu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary cutaneous T-cell lymphomas (CTCLs) are rare lymphoproliferative malignancies characterized by significant morbidity and mortality in advanced disease stages. As curative approaches apart from allogeneic stem cell transplantation are lacking, establishing new treatment options, especially combination therapies, is crucial.
Methods
This retrospective study included 11 patients with SS or MF receiving therapy with mogamulizumab in combination with ECP from four European expert centers. The response rates in the skin and blood as well as treatment use and adverse events (AE) were described.
Results
8/11 patients (73%) showed an overall response (OR) in the skin. The mean mSWAT decreased from 98.2 ± 40.8 to 34.6 ± 23.8. The overall response rate (ORR) in the blood was 64% with two complete responses. During combination therapy, the mean number of Sézary cells decreased from 3365.3 × 106/L before treatment to 1268.6 × 106/L. The mean minimum known period without progress was 7.2 months in the skin and 7.6 months in the blood. The most common AEs were mogamulizumab-associated rash (MAR) (45.5%), anemia (27.3%), lymphocytopenia (27.8%), and infusion related reaction (16.7%). No AE led to treatment discontinuation.
Conclusions
Our study presents the combination of mogamulizumab and ECP as an effective therapy in the blood and skin in CTCL with good tolerability, similar to mogamulizumab monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
- Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany.
- Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
- Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany.
- Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
- Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, 1007 Lausanne, Switzerland.
ORCID-Profile: Nina Booken, Maël Blanchard, Chalid Assaf
Zitieren
APA
Ninosu, N., Melchers, S., Kappenstein, M., Booken, N., Hansen, I., Blanchard, M., Guenova, E., Assaf, C., Goerdt, S., & Nicolay, J. P. (2023). Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma. Cancers, 16(1), 141. https://doi.org/10.3390/cancers16010141
Vancouver
Ninosu N, Melchers S, Kappenstein M, Booken N, Hansen I, Blanchard M, et al. Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma. Cancers. 2023;16(1):141. doi:10.3390/cancers16010141
BibTeX
@article{Ninosu2023,
author = {Ninosu, Nadia and Melchers, Susanne and Kappenstein, Max and Booken, Nina and Hansen, Inga and Blanchard, Maël and Guenova, Emmanuella and Assaf, Chalid and Goerdt, Sergij and Nicolay, Jan P},
title = {Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {141},
doi = {10.3390/cancers16010141}
}
EUVIMED